Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.48 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | BLK | P51451 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hx-1171 SCHEMBL29375871 | 1.00 | ESR1 (0.50) | ESR1ALOX5NR5A1CHUKDAPK3 | |
| SCHEMBL30367452 | 0.93 | ESR1 (0.47) | ESR1ALOX5NR5A1 | |
| SCHEMBL689246 | 0.93 | ESR1 (0.47) | ESR1ALOX5NR5A1 | |
| SCHEMBL25329980 | 0.87 | PTGS1 (0.45) | ESR1ALOX5 | |
| SCHEMBL5588257 | 0.82 | ESR1 (0.47) | ESR1ALOX5NR5A1 | |
| SCHEMBL1375338 | 0.81 | ESR1 (0.48) | ESR1ALOX5NR5A1 | |
| SCHEMBL24784358 | 0.80 | TSHR (0.41) | ESR1ALOX5 | |
| SCHEMBL30356518 | 0.79 | ESR1 (0.45) | ESR1ALOX5NR5A1 | |
| SCHEMBL16069600 | 0.79 | ESR1 (0.42) | ESR1ALOX5NR5A1THRATHRB | |
| SCHEMBL862599 | 0.79 | ESR1 (0.51) | ESR1NR5A1CHUKDAPK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393566-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROQUINONE DERIVATIVE FOR PREVENTING OR TREATING OBESITY OR NONALCOHOLIC STEATOHEPATITIS | BIOTOXTECH CO., LTD. (KR) | 2021-12-23 | — | — | US | claimed |
| CN-112955132-A | Pharmaceutical composition comprising hydroquinone derivative for preventing or treating obesity or non-alcoholic steatohepatitis | 生物毒性技术有限公司 | 2021-06-11 | — | — | CN | claimed |
| WO-2021029656-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NONALCOHOLIC STEATOHEPATITIS, CONTAINING HYDROQUINONE DERIVATIVE AND OBETICHOLIC ACID | 주식회사 바이오톡스텍 | 2021-02-18 | — | — | WO | claimed |
| WO-2020085644-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROQUINONE DERIVATIVE FOR PREVENTING OR TREATING OBESITY OR NONALCOHOLIC STEATOHEPATITIS | 주식회사 바이오톡스텍 | 2020-04-30 | — | — | WO | claimed |
| EP-3287128-A1 | CHRONIC RESPIRATORY DISEASE THERAPEUTIC AGENT AND CARDIAC FIBRILLATION SUPPRESSING COMPOSITION | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2018-02-28 | — | — | EP | claimed |
| US-20180049996-A1 | THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASE AND COMPOSITION FOR INHIBITING CARDIAC FIBROSIS | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2018-02-22 | — | — | US | claimed |
| EP-2052719-B1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LAB INC (JP) | 2013-01-16 | — | — | EP | claimed |
| EP-2110127-B1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LAB INC (JP) | 2012-02-29 | — | — | EP | claimed |
| US-7847132-B2 | Hepatic fibrosis inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2010-12-07 | — | — | US | claimed |
| US-20100184858-A1 | Hepatic fibrosis inhibitor | BIOTOXTECH CO., LTD (KR) | 2010-07-22 | — | — | US | claimed |
| WO-2005016399-A1 | MEDICAL DEVICES CONTAINING ANTIOXIDANT AND THERAPEUTIC AGENT | SCIMED LIFE SYSTEMS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050037048-A1 | Medical devices containing antioxidant and therapeutic agent | BOSTON SCIENTIFIC SCIMED, INC. | 2005-02-17 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20030099694-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG (DE) | 2003-05-29 | — | — | US | claimed |
| CN-1359288-A | Improved method of transport across an adaptable semi-permeable barrier | IDEA AG (DE) | 2002-07-17 | — | — | CN | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1189598-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG (DE) | 2002-03-27 | — | — | EP | claimed |
| CN-1327382-A | Improved formulation for topical non-invasive application in vivo | IDEA INNOVAT DERMALE APPL GMBH (DE) | 2001-12-19 | — | — | CN | claimed |
| WO-2001001963-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG (DE) | 2001-01-11 | — | — | WO | claimed |
| WO-2001001962-A1 | A METHOD FOR THE IMPROVEMENT OF TRANSPORT ACROSS ADAPTABLE SEMI-PERMEABLE BARRIERS | IDEA AG. (DE) | 2001-01-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184858-A1 | Hepatic fibrosis inhibitor | HDGF, HAVCR2, FABP1 | ESR1 4553/4885ALOX5 1889/4885NR5A1 1812/4885 |
| US-20180049996-A1 | THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASE AND COMPOSITION FOR INHIBITING CARDIAC FIBROSIS | TNNI3, TNNT2, MMP1 | ESR1 4190/4885ALOX5 251/4885NR5A1 2279/4885 |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | ESR1 4144/4885ALOX5 49/4885NR5A1 3703/4885 |
| US-20210393566-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROQUINONE DERIVATIVE FOR PREVENTING OR TREATING OBESITY OR NONALCOHOLIC STEATOHEPATITIS | CPT1A, PLIN1, LIPC | ESR1 2774/4885ALOX5 413/4885NR5A1 60/4885 |
| US-20030099694-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | ABCG2, NPC1L1, KIT | ESR1 4527/4885ALOX5 684/4885NR5A1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.